Anaplastic Large Cell Lymphoma
View / Open Files
Authors
D. Turner, Suzanne
Publication Date
2019-08-07Publisher
IntechOpen
Type
Book chapter
Metadata
Show full item recordCitation
D. Turner, S. (2019). Anaplastic Large Cell Lymphoma. [Book chapter]. https://doi.org/10.5772/intechopen.81382
Abstract
Anaplastic Large Cell Lymphoma (ALCL) describes a distinct group of T cell lymphomas characterized by cell surface expression of CD30. At least 3 entities of ALCL exist, with similar cellular morphology but varying clinical courses and pathology: systemic ALCL, Anaplastic Lymphoma Kinase (ALK)-positive, systemic ALCL ALK- and primary cutaneous ALCL. A fourth provisional entity associated with breast implants has been proposed, named breast implant-associated (BIA)-ALCL. ALCL have varying clinical outcomes, affect both children and adults, and range from being well-characterised at the genetic level to relatively unknown, predominantly due to the relative rarity of this group of malignancies. Current therapeutic approaches include standard chemotherapeutic agents as well as novel drugs including monoclonal antibodies and kinase inhibitors.
Sponsorship
Leukaemia & Lymphoma Research (12065)
Identifiers
External link: https://www.intechopen.com/chapters/63776
External DOI: https://doi.org/10.5772/intechopen.81382
This record's DOI: https://doi.org/10.17863/CAM.75240
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.